Lates News

Boehringer Ingelheim (BIIB) and Japan's Eisai have received approval from the US Food and Drug Administration (FDA) for a home therapy for the treatment of Alzheimer's disease. Leqembi Iqlik is a self-administered injectable drug that patients can use at home under supervision after 18 months of initial treatment. The product is scheduled to be launched in the US market on October 6th.